Blog
RSS FeedPosted by Michael Wonder on 18 Jun 2025
Cancer inhibitors scrapped from basic insurance for some users
18 June 2025 - National health care institute Zorginstituut Nederland has scrapped several cancer inhibiting drugs from the basic health ...
Posted by Michael Wonder on 19 Jun 2025
Tislelizumab for the treatment of adults with advanced non-small-cell lung cancer after platinum-based chemotherapy
19 June 2025 - NICE is unable to make a recommendation on the use of tislelizumab (Tevimbra) for the treatment of ...
Posted by Michael Wonder on 19 Jun 2025
Atezolizumab for the adjuvant treatment of patients with resected non-small-cell lung cancer
19 June 2025 - NICE has published final evidence-based recommendations on the use of atezolizumab (Tecentriq) for the adjuvant treatment ...
Posted by Michael Wonder on 19 Jun 2025
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
16 June 2025 - With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be ...
Posted by Michael Wonder on 19 Jun 2025
Kye Pharmaceuticals receives Health Canada approval for new dosing guidance for Firdapse and an additional paediatric indication
17 June 2025 - Kye Pharmaceuticals today announced that Health Canada has approved its supplemental new drug submission regarding the recommended ...
Posted by Michael Wonder on 19 Jun 2025
Health Canada approves Novartis' Kisqali for HR positive, HER2 negative early breast cancer patients at high risk of recurrence
18 June 2025 - Health Canada approval is based on the pivotal Phase 3 NATALEE trial data, which demonstrated a clinically ...
Posted by Michael Wonder on 18 Jun 2025
PHARMAC funding U turn for patients
16 June 2025 - Associate Health Minister David Seymour says the oestradiol patch funding decision is an example of PHARMAC’s ...
Posted by Michael Wonder on 18 Jun 2025
PHARMAC to fund two brands of oestradiol patches from 1 December 2025
16 June 2025 - PHARMAC will fund two brands of oestradiol patches – Estradot and Estradiol TDP Mylan – from ...
Posted by Michael Wonder on 18 Jun 2025
FDA to issue new Commissioner’s national priority vouchers to companies supporting US national interests
17 June 2025 - The US FDA today announced its Commissioner’s National Priority Voucher program to enhance the health interests of ...
Posted by Michael Wonder on 18 Jun 2025
Aldeyra Therapeutics resubmits reproxalap new drug application for the treatment of dry eye disease
17 June 2025 - Aldeyra Therapeutics today announced the resubmission of a new drug application to the US FDA for ...
Posted by Michael Wonder on 18 Jun 2025
FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
18 June 2025 - Today, the FDA approved tafasitamab-cxix (Monjuvi, Incyte) with lenalidomide and rituximab for adults with relapsed or ...
Posted by Michael Wonder on 18 Jun 2025
Yeztugo (lenacapavir) is now the first and only FDA approved HIV prevention option offering 6 months of protection
18 June 2025 - Approval based on Phase 3 PURPOSE 1 and PURPOSE 2 data that showed ≥99.9% of participants remained ...
Posted by Michael Wonder on 18 Jun 2025
Bavarian Nordic announces sale of priority review voucher for USD 160 million
18 June 2025 - Bavarian Nordic announced today that it has entered into an agreement to sell its priority review ...
Posted by Michael Wonder on 18 Jun 2025
Obecabtagene autoleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia
13 June 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 18 Jun 2025
Duke Street Bio receives FDA fast track designation for DSB2455
10 June 2025 - Duke Street Bio today announced that the US FDA has granted fast track designation to DSB2455, its ...